Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lessened its stake in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 71.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 168,500 shares of the company's stock after selling 423,123 shares during the period. Schonfeld Strategic Advisors LLC owned 0.25% of Perspective Therapeutics worth $538,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd bought a new stake in shares of Perspective Therapeutics in the fourth quarter valued at about $33,000. Aigen Investment Management LP purchased a new position in Perspective Therapeutics during the 4th quarter valued at about $34,000. National Bank of Canada FI raised its holdings in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after purchasing an additional 10,998 shares in the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of Perspective Therapeutics in the 4th quarter worth approximately $51,000. Finally, Virtus ETF Advisers LLC boosted its stake in shares of Perspective Therapeutics by 157.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 20,487 shares of the company's stock valued at $65,000 after purchasing an additional 12,542 shares in the last quarter. Institutional investors own 54.66% of the company's stock.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, Director Robert F. Williamson III bought 22,192 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average price of $2.27 per share, with a total value of $50,375.84. Following the completion of the acquisition, the director now directly owns 70,837 shares in the company, valued at approximately $160,799.99. This trade represents a 45.62% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Johan M. Spoor bought 22,026 shares of the firm's stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the transaction, the chief executive officer now directly owns 59,383 shares of the company's stock, valued at $133,017.92. This trade represents a 58.96% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 115,696 shares of company stock worth $256,344. 3.72% of the stock is currently owned by insiders.

Perspective Therapeutics Price Performance

Shares of NYSE CATX traded up $0.04 during mid-day trading on Tuesday, hitting $2.55. The stock had a trading volume of 944,738 shares, compared to its average volume of 1,029,626. The company has a 50 day moving average of $2.26 and a two-hundred day moving average of $3.85. Perspective Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $19.05.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Truist Financial reduced their price objective on shares of Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, April 7th. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research note on Monday, March 31st. Scotiabank began coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price for the company. Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Finally, Wedbush reiterated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday. One analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $12.75.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.